Evidence map›Paper›PMID 31569697›Full record

ArticleMolecules (Basel, Switzerland)2019

Development of

Yang Zhou, Abid H Banday, Victor J Hruby, Minying Cai

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Stereoisomeric PamRSC medicinal chemistry · 2022
    Article
  2. Review
  3. Antioxidant and Anti-Inflammatory Effects ofFoods (Basel, Switzerland) · 2021
    Article
  4. Engineering Targeting Materials for Therapeutic Cancer Vaccines.Frontiers in bioengineering and biotechnology · 2020
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yang ZhouDepartment of Chemistry and Biochemistry, The University of Arizona, Tucson, AZ 85721, USA. yangzhou@email.arizona.edu.ORCID 0000-0001-5199-156X
Abid H BandayDepartment of Chemistry and Biochemistry, The University of Arizona, Tucson, AZ 85721, USA. abidrrl@gmail.com.
Victor J HrubyDepartment of Chemistry and Biochemistry, The University of Arizona, Tucson, AZ 85721, USA. hruby@email.arizona.edu.
Minying CaiDepartment of Chemistry and Biochemistry, The University of Arizona, Tucson, AZ 85721, USA. mcai@email.arizona.edu.ORCID 0000-0001-9504-2091
University of Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer vaccine is a promising immunotherapeutic approach to train the immune system with vaccines to recognize and eliminate tumors. Adjuvants are compounds that are necessary in cancer vaccines to mimic an infection process and amplify immune responses. The Toll-like receptor 2 and 6 (TLR2/TLR6) agonist dipalmitoyl-

Indexed as

HumansLipopeptidesMolecular ConformationMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureToll-Like Receptor 2Toll-Like Receptor 6LipopeptidesS-(2,3-bis(palmitoyloxy)propyl)cysteineToll-Like Receptor 2Toll-Like Receptor 6adjuvantcancer vaccineN-acetylated Pam2CysPam2Cyssynthetic vaccineToll-like receptor

Identifiers

PMID31569697
PMCPMC6803979
OpenAlexW2976793510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.